Here are Wednesday's top research calls, including upgrades for Goldman Sachs, Celanese and SBA Communications.
For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!
AstraZeneca's Lynparza significantly delayed the recurrence of tumors in patients with ovarian cancer compared to a placebo, according to results from a phase III study announced by the company Wednesday.
U.S. stocks closed higher Monday as oil prices gained steam and Wall Street looked ahead to the start of earnings season.